查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1918083

关节疼痛注射剂市场－2026-2031年预测

Joint Pain Injections Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 143 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计关节疼痛注射市场将从 2025 年的 61.11 亿美元成长到 2031 年的 93.64 亿美元，复合年增长率为 7.37%。

关节疼痛注射市场呈现显着上升趋势，主要驱动因素是全球骨关节炎和关节炎等肌肉骨骼疾病发生率的不断上升。这些疾病严重影响患者的活动能力和生活质量，因此对有效的疼痛管理方案的需求很大。全球人口老化是加剧此需求的重要人口因素。关节疼痛注射（关节内注射）是一种微创手术，可将药物直接输送到关节内，以缓解疼痛和发炎。与全身性口服药物和手术相比，关节疼痛注射具有恢復时间短、疗效持久等优势，已成为现代整形外科治疗和慢性疼痛管理的基础。

关键市场驱动因素与限制因素

市场扩张的主要驱动因素是全球关节疾病风险因子的增加。肥胖症的日益普及给关节带来过大的机械负荷，增加了功能障碍和退化性疾病的风险。此外，久坐的生活方式会导致支撑肌肉力量减弱，进一步加剧关节脆弱性。人口结构转变为老化也是一个根本性的驱动因素，因为老龄化是骨关节炎发生的主要风险因素。

一个值得关注的市场趋势是再生医学的日益普及。传统的注射疗法，例如皮质类固醇和透明质酸，透过减轻发炎和补充关节液来缓解症状，而富血小板血浆（PRP）和干细胞疗法等再生疗法则旨在修復组织并促进关节的长期健康。越来越多的临床证据支持其疗效，患者对非手术治疗方案的需求，以及细胞治疗方法生产技术的进步，共同推动这些先进治疗方法走向主流。

然而，市场成长也面临一些限制因素。高昂的治疗费用，尤其是再生医学和需要多次注射的疗程，可能会限制病患的就医途径。这项挑战源自于保险覆盖范围有限或参差不齐，往往导致患者需要承担高额的自付费用。此外，还有许多替代治疗方法，包括物理疗法、口服止痛药、非类固醇消炎剂（NSAIDs）和辅助器具，它们与注射疗法有竞争关係，尤其是在治疗轻度至中度关节疼痛方面。

市场区隔与区域展望

市场按产品和关节类型细分。依产品划分，玻尿酸注射占较大的市场份额，因其能有效缓解骨关节炎疼痛并改善活动能力而闻名。按关节类型划分，膝关节细分市场占据最大的市场份额，这主要归因于膝骨关节炎的高发病率以及膝关节承受的巨大压力。

从区域来看，北美市场占据主导地位。其主导地位得益于慢性关节疾病的高发生率、完善的医疗保健基础设施以及创新治疗方法的快速普及。欧洲也是一个成熟的市场，其特点是强大的製药业和持续的医疗进步。

亚太地区预计将成为成长最快的地区，这主要得益于庞大且老化的人口、不断提高的健康意识、不断扩建的医院基础设施以及对医药研发投入的增加。南美洲和中东及非洲市场正在发展，成长主要集中在较富裕的都市区。医疗保健投资的增加、医疗旅游的兴起以及患者健康意识的提高正在推动这些地区的扩张，但由于基础设施和成本的限制，遍远地区的医疗服务仍然有限。

竞争格局与策略趋势

市场竞争激烈，由跨国製药和生技公司主导。主要企业正积极推行策略倡议以巩固其市场地位。这些措施包括：大力开展以创新治疗方法为重点的研发项目；建立策略联盟和伙伴关係，以增强产品系列和分销网络；以及拓展地域，将创新产品推向新市场。持续专注于创新，尤其是在再生医学和先进治疗解决方案领域，是塑造竞争格​​局的关键因素。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及影响、新产品开发、竞争影响

分析范围

  • 历史资料（2021-2025 年）和预测资料（2026-2031 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

第五章 关节疼痛注射市场（按类型划分）

  • 介绍
  • 皮质类固醇
  • 玻尿酸注射
  • 富血小板血浆（PRP）注射
  • 其他的

第六章 依关节类型分類的关节疼痛注射市场

  • 介绍
  • 膝关节
  • 手腕关节
  • 髋关节
  • 其他的

第七章 依最终使用者分類的关节疼痛注射剂市场

  • 介绍
  • 医院
  • 诊所
  • 其他的

第八章 各地区关节疼痛注射市场

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十章：公司简介

  • Sanofi
  • Seikagaku Corporation
  • Bioventus
  • Anika Therapeutics, Inc.
  • Pacira BioSciences, Inc.
  • Dr. Reddy's Laboratories Ltd
  • Zimmer Biomet
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd.
  • Ferring Pharmaceuticals
  • Eli Lilly And Company

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061615514

Joint Pain Injections Market is expected to grow at a 7.37% CAGR, achieving USD 9.364 billion in 2031 from USD 6.111 billion in 2025.

The joint pain injections market is experiencing a significant uptrend, primarily driven by the rising global incidence of musculoskeletal conditions such as osteoarthritis and arthritis. These conditions profoundly impact patient mobility and quality of life, creating a substantial demand for effective pain management solutions. The growing elderly population worldwide is a key demographic factor amplifying this need. Joint pain injections, or intra-articular injections, represent a minimally invasive procedure where medication is administered directly into the joint to relieve pain and inflammation. Their appeal lies in offering faster recovery times and longer-lasting effects compared to systemic oral medications or surgical interventions, making them a cornerstone of modern orthopedic care and chronic pain management.

Primary Market Growth Drivers and Restraints

A major driver for market expansion is the global increase in risk factors for joint disease. The rising prevalence of obesity places excessive mechanical strain on joints, elevating the risk of dysfunction and degenerative conditions. Coupled with this, sedentary lifestyles can lead to weakened supporting musculature, further contributing to joint vulnerability. The demographic shift towards an older population is another fundamental driver, as age is a primary risk factor for the development of osteoarthritis.

A defining trend within the market is the rising adoption of regenerative therapies. While traditional injections like corticosteroids and hyaluronic acid provide symptomatic relief by reducing inflammation and supplementing joint fluid, regenerative options such as platelet-rich plasma (PRP) and stem cell therapies aim to promote tissue repair and long-term joint health. Growing clinical evidence supporting their efficacy, patient demand for alternatives to surgery, and technological advancements in cell therapy production are collectively propelling these sophisticated options into the mainstream.

However, the market's growth is tempered by certain restraints. The high cost of treatment, particularly for regenerative therapies and courses requiring multiple injections, can limit patient access. This challenge is often compounded by limited or variable insurance coverage, resulting in significant out-of-pocket expenses. Furthermore, a range of alternative treatments exists, including physical therapy, oral analgesics, NSAIDs, and assistive devices, which compete with injections, especially for managing mild to moderate joint pain.

Market Segmentation and Regional Outlook

The market is segmented by product and joint type. In terms of products, hyaluronic acid injections have secured a significant market share, valued for their ability to alleviate pain and improve mobility in osteoarthritic joints. Regarding joint type, the knee segment represents the largest market share, attributable to the high prevalence of knee osteoarthritis and the considerable stress the knee joint endures.

Geographically, North America holds a leading position in the market. This dominance is supported by a high prevalence of chronic joint diseases, a well-developed healthcare infrastructure, and a rapid rate of adoption for innovative therapies. Europe also represents a mature market, characterized by a strong pharmaceutical sector and continuous medical advancements.

The Asia-Pacific region is anticipated to witness the most rapid growth. This is fueled by a large and aging population, increasing healthcare awareness, expanding hospital infrastructure, and growing investments in pharmaceutical research and development. Markets in South America and the Middle East & Africa are developing, with growth concentrated in more affluent, urban areas. In these regions, expansion is driven by rising healthcare investment, growing medical tourism, and increasing patient awareness, though access remains limited in rural areas due to infrastructure and cost constraints.

Competitive Landscape and Strategic Developments

The market is competitively served by a mix of multinational pharmaceutical and biotechnology companies. Key players are actively engaged in strategic initiatives to strengthen their market position. These strategies include robust research and development programs focused on novel therapies, strategic collaborations and partnerships to enhance product portfolios and distribution, and geographic expansion efforts to commercialize innovative products in new markets. The competitive dynamics are shaped by a continuous focus on innovation, particularly in the realm of regenerative medicine and advanced therapeutic solutions.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Joint Pain Injections Market Segmentation:

  • By Type
  • Corticosteroid
  • Hyaluronic Acid Injections
  • Platelet Rich Plasma (PRP) Injections
  • Others
  • By Joint Type
  • Knee Joint
  • Hands & Wrist Joint
  • Hip Joint
  • Others
  • By End-User
  • Hospitals
  • Clinics
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. JOINT PAIN INJECTIONS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Corticosteroid
  • 5.3. Hyaluronic Acid Injections
  • 5.4. Platelet Rich Plasma (PRP) Injections
  • 5.5. Others

6. JOINT PAIN INJECTIONS MARKET BY JOINT TYPE

  • 6.1. Introduction
  • 6.2. Knee Joint
  • 6.3. Hands & Wrist Joint
  • 6.4. Hip Joint
  • 6.5. Others

7. JOINT PAIN INJECTIONS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Clinics
  • 7.4. Others

8. JOINT PAIN INJECTIONS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Italy
    • 8.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Sanofi
  • 10.2. Seikagaku Corporation
  • 10.3. Bioventus
  • 10.4. Anika Therapeutics, Inc.
  • 10.5. Pacira BioSciences, Inc.
  • 10.6. Dr. Reddy's Laboratories Ltd
  • 10.7. Zimmer Biomet
  • 10.8. Pfizer Inc
  • 10.9. Teva Pharmaceutical Industries Ltd.
  • 10.10. Ferring Pharmaceuticals
  • 10.11. Eli Lilly And Company

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations